New shot could slash severe asthma attacks in half
NCT ID NCT05472324
First seen Nov 20, 2025 · Last updated May 06, 2026 · Updated 21 times
Summary
This study tested an investigational drug called TQC2731 in 205 adults with severe asthma that is not well controlled by current treatments. Participants received either one of three doses of TQC2731 or a placebo as a shot every 4 weeks for 48 weeks. The main goal was to see if the drug could reduce the number of asthma attacks over a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GUANGZHOU FIRST PEOPLE's HOSPITAL
Guangzhou, Guangdong, 510180, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.